Haematologist @KingsCollegeNHS @myeloidkings #StemcellTransplantation #GVHD #MedicalMycology #loveToNetwork #BloodCancerResearch
London, England
Joined September 2012
- Tweets330
- Following337
- Followers453
- Likes3.9K
Varun Mehra retweeted
In a randomized phase 2 trial involving adults with AML, azacitidine–venetoclax led to longer event-free survival than induction chemotherapy, with a lower risk of severe infection and hemorrhage. Full PARADIGM trial results: nej.md/4zJr1wV
Editorial: Hypomethylating Agents plus Venetoclax as Compared with Intensive Chemotherapy in Patients with AML nej.md/4cgnBHO
ALT Shown are Kaplan–Meier curves for event-free survival (Panel A) and overall survival (Panel B) in the azacitidine–venetoclax and induction chemotherapy groups.
Varun Mehra retweeted
CONGRESS | #EHA2026 | PRESENTATION
Johannes Schetelig presents findings from a randomized non-inferiority trial evaluating PTCy-100 vs ATLG-30 as #GvHD prophylaxis in allo-HSCT recipients from unrelated donors (N = 640).
In the ITT population, the 2-year OS was 68% with PTCy-100 vs 75% with ATLG-30 (HR, 1.341; test for non-inferiority, p = 0.85; test for superiority, p = 0.051). The 2-year GRFS was 48% with PTCy-100 vs 40% with ATLG-30 (HR, 0.85; p = 0.16). The 2-year cumulative incidences of relapse were 26% and 31% (HR, 0.86), respectively. The 2-year NRM was 13% with PTCy-100 vs 7% with ATLG-30 (HR, 1.86; p = 0.02). Overall, confirmatory testing demonstrated that non-inferior survival with a 5% margin for PTCy-100 compared with ATLG-30 could not be shown.
Follow our live feed for more updates: loom.ly/1BscQNI
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#GvHDsm #MedicalCongress @DKMS_SciMed
#EHA2026 #excitement #Stockholm
Look forward to share my thoughts in Challenges in Infection Complications with Transplant and Cellular therapies.
And ofcourse see some friends!
Varun Mehra retweeted
Original Article: Obexelimab for the Treatment of IgG4-Related Disease (phase 3 INDIGO trial results) nej.md/4fKYQG4
Editorial: Obexelimab and the Promise of Nondepleting B-Cell Therapy in IgG4-Related Disease nej.md/4fLybcd
#EULAR2026 | @eular_org
ALT Graph showing estimates over time of the probability of a first flare of IgG4-related disease for which rescue therapy was required. The y-axis represents the probability of no flare, ranging from 0 to 1, and the x-axis shows time in months. The blue line indicates obexelimab while gray line indicates placebo. Notable statistics detail patients at risk, number of patients with flares, and median times. The hazard ratio is 0.44 with a p-value of <0.001.
ALT The image displays two line graphs. The top graph shows CD20+ B-cell counts over time in weeks, comparing placebo and obexelimab treatments. The bottom graph presents serum IgG4 levels. Both graphs include patient numbers at different stages.
Varun Mehra retweeted
Looking for a new Professor of Haematology and Head of the Department of Haematology at King's College London, based in the Denmark Hill campus. Closing date: May 4. For more info: kcl.ac.uk/jobs/142085-profes…
@KHPHaematology
@KCLcancer_pharm
@KCLredcell
@kingsmedicine
Varun Mehra retweeted
American Society of Hematology 2026 Guidelines for the Diagnosis and Management of Severe Acquired Aplastic Anemia | Blood Advances | American Society of Hematology ashpublications.org/bloodadv…
#Mycology2026 start today! Everything related to Fungal diseases with some excellent line up of speakers, new updates and innovations in the field!
Come join for some exciting interactions and networking with experts in the field.
@FungalUpdate
mycologyconference.co.uk/age…
Varun Mehra retweeted
CONGRESS | #EBMT26 | PRESENTATION
Florent Malard reports final results from the phase III, multicenter, open-label ARES trial, evaluating MaaT013 as a third-line treatment option in patients with treatment-refractory GI-#aGvHD after systemic steroids and ruxolitinib (N = 66). ARES met its primary endpoint, with a Day 28 GI-ORR of 62%, exceeding the pre-established threshold of 22% (p < 0.0001). Most patients had Day 28 GI-CR (38%) or GI-VGPR (20%), with 5% experiencing GI-PR. The all-organ ORR at Day 28 was 64%, and GI-ORR was maintained in 47% at Day 56 and 44% at Month 3. With a median follow-up of 344.5 days, the median OS was not reached; OS was 54% at Month 12, and was higher among Day 28 responders vs non-responders (68% vs 28%).
Follow our live feed for more updates: bit.ly/4lyVG9v
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#GvHDsm #MedNews #MedEd @TheEBMT @Florent_Malard @crsa_paris
Super important piece for GVHD community.
Chronic graft-versus-host disease: Current situation and unmet needs — A European position statement | Bone Marrow Transplantation @Mohty_EBMT nature.com/articles/s41409-0…
Time to step up and diligently apply regulatory framework for emerging novel therapeutic class (SoHO, Substances of Human Origin) in #HSCT and #GVHD.
@Mohty_EBMT @TheEBMT
nature.com/articles/s41409-0…
Varun Mehra retweeted
CONGRESS | #ASH25 | POSTER
Everett Meyer presents data from a subgroup analysis of the phase III Precision-T trial of Orca-T versus tacrolimus + methotrexate (Tac/MTX) in patients with acute leukemia (N = 182).
At 1 year, Orca-T demonstrated improved rates of chronic GvHD-free survival (78% vs 38%; p < 0.0001), OS (94% vs 83%; p = 0.045), GRFS (63% vs 31%; p < 0.0001), and NRM (13% vs 3.4%; p = 0.037) compared to Tac/MTX. Orca-T vs Tac/MTX showed improved clinical outcomes across patient subgroups with varied demographic and clinical features, including age, sex, donor type, and conditioning regimen.
Follow our live feed for more updates: loom.ly/MbPzIiA
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#GvHD #GvHDsm #MedicalCongress @StanfordMed
Inviting all HCPs involved in care for stem cell transplant patients to our 1st KHP Preceptorship Event (3/4th Sept 2025) for Transplant complications with #GVHD
This is a limited space event, so book early..
Registration/program details below..
eventbrite.co.uk/e/graft-ver…
Varun Mehra retweeted
AML at @EHA_Hematology 2025: Inqovi, Ziftomenib, Bleximenib, and More.
Key updates on ORR, CR/CRi rates, and tolerability.
Follow us for the latest #EHA2025 updates: t.ly/6uoHY
#LARVOL #AML #Hematology #CancerResearch #Oncology #CancerData #OncologyInsights | @Dr_AmerZeidan | @AlkaliDr | @LeukDocJZ | @calliecoombsmd | @hemedoc | @AaronGoodman33 | @TalhaBadarMD | @SuyogCancer
Varun Mehra retweeted
Original Article: Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin (ALLG BM12 CAST phase 3 trial) nej.md/3Zpri7z
#EHA2025 | @EHA_Hematology
ALT A graph showing the primary end point, which was graft-versus-host disease (GVHD)–free, relapse-free survival.
ALT A graph showing relapse-free survival, which was assessed in a post hoc exploratory analysis.
ALT A graph showing overall survival, which was a secondary end point.
Varun Mehra retweeted
Menin inhibitor studies at @EHA_Hematology 2025 in acute leukemia, focusing on NPM1-mutated and KMT2A-rearranged subsets.
Follow us for the latest #EHA2025 updates: t.ly/6uoHY
#LARVOL #Hematology #Leukemia #CancerResearch #Oncology #CancerData #OncologyInsights | @Dr_AmerZeidan | @TalhaBadarMD | @smbenlazar | @hemedoc | @LeukDocJZ | @Abdallah81MD | @SuyogCancer
Varun Mehra retweeted
a comprehensive report of the survival outcomes among 240 patients who underwent a transplant at the MD Anderson Cancer Center for acute myeloid leukemia AML or myelodysplastic syndrome with TP53 mutations over a 10-year period. ow.ly/Y03x50W7qaE #transplantation
Hot off the press!
Our UK wide 20years experience of Autologous #HSCT in #MultipleSclerosis reaffirming its significant benefits even with advanced disability
@BSBMT @BritSocHaem @BrJHaem @TheEBMT @KingsCollegeNHS @mssocietyuk @MSTrust
Key findings👇🏻
doi.org/10.1111/bjh.20199
3. First report confirming more immunosuppression i.e. higher ATG doses do not confer additional benefit. Harmonised dosing essential!
4. Transplant related Mortality risk <1.5%, mainly seen with advanced disability and needs better optimisation/ careful selection essential
